Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip van den Bosch

Showing results (151-160 of 193) with videos related to

Pageof 20
Sort By:
Arthritis and Rheumatism|July 27, 2006
A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritisJasper J Haringman, Danielle M Gerlag, Tom J M Smeets, et al.
Annals of the Rheumatic Diseases|July 15, 2019
Low specificity but high sensitivity of inflammatory back pain criteria in rheumatology settings in Europe: confirmation of findings from a German cohort studyManouk de Hooge, Floris A van Gaalen, Thomas Renson, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 10, 2018
Association of Inflammatory Bowel Disease and Acute Anterior Uveitis, but Not Psoriasis, With Disease Duration in Patients With Axial Spondyloarthritis: Results From Two Belgian Nationwide Axial Spondyloarthritis CohortsGaëlle Varkas, Nathan Vastesaeger, Heleen Cypers, et al.
Annals of the Rheumatic Diseases|September 7, 2025
ASAS recommendations on reporting axial spondyloarthritis clinical trialsFloris A van Gaalen, Victoria Navarro-Compán, Xenofon Baraliakos, et al.
Lancet (London, England)|October 27, 2018
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trialDésirée van der Heijde, James Cheng-Chung Wei, Maxime Dougados, et al.
Annals of the Rheumatic Diseases|August 14, 2015
Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK studyWalter P Maksymowych, Maxime Dougados, Désirée van der Heijde, et al.
Rheumatology (Oxford, England)|May 13, 2017
Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpADésirée van der Heijde, Maxime Dougados, Robert Landewé, et al.
Arthritis Research & Therapy|October 7, 2005
DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatmentBert Vander Cruyssen, Stijn Van Looy, Bart Wyns, et al.
Arthritis Research & Therapy|May 16, 2023
Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritisJuergen Braun, Ricardo Blanco, Helena Marzo-Ortega, et al.
Arthritis Research & Therapy|September 5, 2021
Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENTJürgen Braun, Ricardo Blanco, Helena Marzo-Ortega, et al.
Pageof 20

Showing results (151-160 of 193) with videos related to

Sort By:
Pageof 20
Arthritis and Rheumatism|July 27, 2006
A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritisJasper J Haringman, Danielle M Gerlag, Tom J M Smeets, et al.
Annals of the Rheumatic Diseases|July 15, 2019
Low specificity but high sensitivity of inflammatory back pain criteria in rheumatology settings in Europe: confirmation of findings from a German cohort studyManouk de Hooge, Floris A van Gaalen, Thomas Renson, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 10, 2018
Association of Inflammatory Bowel Disease and Acute Anterior Uveitis, but Not Psoriasis, With Disease Duration in Patients With Axial Spondyloarthritis: Results From Two Belgian Nationwide Axial Spondyloarthritis CohortsGaëlle Varkas, Nathan Vastesaeger, Heleen Cypers, et al.
Annals of the Rheumatic Diseases|September 7, 2025
ASAS recommendations on reporting axial spondyloarthritis clinical trialsFloris A van Gaalen, Victoria Navarro-Compán, Xenofon Baraliakos, et al.
Lancet (London, England)|October 27, 2018
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trialDésirée van der Heijde, James Cheng-Chung Wei, Maxime Dougados, et al.
Annals of the Rheumatic Diseases|August 14, 2015
Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK studyWalter P Maksymowych, Maxime Dougados, Désirée van der Heijde, et al.
Rheumatology (Oxford, England)|May 13, 2017
Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpADésirée van der Heijde, Maxime Dougados, Robert Landewé, et al.
Arthritis Research & Therapy|October 7, 2005
DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatmentBert Vander Cruyssen, Stijn Van Looy, Bart Wyns, et al.
Arthritis Research & Therapy|May 16, 2023
Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritisJuergen Braun, Ricardo Blanco, Helena Marzo-Ortega, et al.
Arthritis Research & Therapy|September 5, 2021
Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENTJürgen Braun, Ricardo Blanco, Helena Marzo-Ortega, et al.
Pageof 20